Esperion Therapeutics (ESPR)
3.15
+0.01 (0.32%)
Upcoming Events
Latest Headlines
Form 8-K Esperion Therapeutics, For: Jun 02
June 9, 2026 4:01 PM - SEC Filing
Form SCHEDULE 13G Esperion Therapeutics, Filed by: GLAZER CAPITAL, LLC
June 8, 2026 5:10 PM - SEC Filing
Form DEFM14A Esperion Therapeutics,
June 8, 2026 6:03 AM - SEC Filing
Form 4 Esperion Therapeutics, For: May 28 Filed by: THOMPSON JOHN CRAIG
June 1, 2026 4:24 PM - SEC Filing
Form 4 Esperion Therapeutics, For: May 28 Filed by: Shepard Jay
June 1, 2026 4:24 PM - SEC Filing
Form 4 Esperion Therapeutics, For: May 28 Filed by: Hoffman Robert E.
June 1, 2026 4:23 PM - SEC Filing
Form 4 Esperion Therapeutics, For: May 28 Filed by: Fischer Seth H. Z.
June 1, 2026 4:23 PM - SEC Filing
Form 4 Esperion Therapeutics, For: May 28 Filed by: CARROLL J MARTIN
June 1, 2026 4:22 PM - SEC Filing
Form 8-K Esperion Therapeutics, For: May 28
June 1, 2026 4:22 PM - SEC Filing
Form PREM14A Esperion Therapeutics, For: May 29
May 29, 2026 5:17 PM - SEC Filing
Esperion presents pediatric bempedoic acid data at European congress
May 26, 2026 8:00 AM - StreetInsider
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
May 26, 2026 8:00 AM - StreetInsider
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 14, 2026 4:30 PM - StreetInsider
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026
May 13, 2026 8:00 AM - Globe NewsWire
Form 10-Q Esperion Therapeutics, For: Mar 31
May 8, 2026 4:12 PM - SEC Filing
Form DEFA14A Esperion Therapeutics,
May 4, 2026 4:05 PM - SEC Filing
Needham Downgrades Esperion Therapeutics (ESPR) to Hold
May 4, 2026 3:11 PM - StreetInsider
Form DEFA14A Esperion Therapeutics,
May 1, 2026 4:00 PM - SEC Filing
Jefferies Downgrades Esperion Therapeutics (ESPR) to Hold, PT to $3.28
May 1, 2026 3:15 PM - StreetInsider
Piper Sandler Downgrades Esperion Therapeutics (ESPR) to Neutral
May 1, 2026 1:56 PM - StreetInsider
Form 8-K Esperion Therapeutics, For: May 01
May 1, 2026 11:50 AM - SEC Filing
Form DEFA14A Esperion Therapeutics,
May 1, 2026 11:50 AM - SEC Filing
H.C. Wainwright Downgrades Esperion Therapeutics (ESPR) to Neutral
May 1, 2026 9:36 AM - StreetInsider
Cantor Fitzgerald Downgrades Esperion Therapeutics (ESPR) to Neutral
May 1, 2026 8:38 AM - StreetInsider
ARCHIMED to acquire Esperion for $3.16 per share plus milestone payments
May 1, 2026 7:01 AM - StreetInsider
Esperion to be Acquired by ARCHIMED
May 1, 2026 7:00 AM - Globe NewsWire
Esperion to Report First Quarter 2026 Financial Results on May 7
April 23, 2026 8:02 AM - Globe NewsWire
Form SCHEDULE 13G Esperion Therapeutics, Filed by: WASATCH ADVISORS LP
April 22, 2026 3:45 PM - SEC Filing
Form ARS Esperion Therapeutics, For: Dec 31
April 16, 2026 4:16 PM - SEC Filing
Form DEFA14A Esperion Therapeutics,
April 16, 2026 4:13 PM - SEC Filing
Form DEF 14A Esperion Therapeutics, For: Apr 16
April 16, 2026 4:12 PM - SEC Filing
Form 8-K Esperion Therapeutics, For: Apr 02
April 2, 2026 4:22 PM - SEC Filing
Esperion secures $50M royalty financing from Athyrium for acquisition
April 2, 2026 4:05 PM - StreetInsider
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
April 2, 2026 4:05 PM - StreetInsider
Esperion completes acquisition of Corstasis for nasal diuretic drug
April 2, 2026 4:00 PM - StreetInsider
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
April 2, 2026 4:00 PM - StreetInsider
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
March 31, 2026 8:00 AM - StreetInsider
Esperion presents stroke reduction data for NEXLETOL at cardiology conference
March 30, 2026 8:05 AM - StreetInsider
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
March 30, 2026 8:00 AM - StreetInsider
Form SCHEDULE 13G/A Esperion Therapeutics, Filed by: VANGUARD GROUP INC
March 26, 2026 6:22 PM - SEC Filing
Form 4 Esperion Therapeutics, For: Mar 17 Filed by: Looker Benjamin
March 18, 2026 4:14 PM - SEC Filing
Form 4 Esperion Therapeutics, For: Mar 17 Filed by: Koenig Sheldon L.
March 18, 2026 4:14 PM - SEC Filing
Form 4 Esperion Therapeutics, For: Mar 17 Filed by: Halladay Benjamin
March 18, 2026 4:14 PM - SEC Filing
Form 144 Esperion Therapeutics, Filed by: Halladay Benjamin
March 17, 2026 3:20 PM - SEC Filing
Form 144 Esperion Therapeutics, Filed by: Looker Benjamin
March 17, 2026 3:18 PM - SEC Filing
Form 144 Esperion Therapeutics, Filed by: Koenig Sheldon L.
March 17, 2026 3:13 PM - SEC Filing
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
March 17, 2026 8:00 AM - StreetInsider
BofA maintains Underperform on Esperion Therapeutics (ESPR) despite favorable new AHA/ACC guidelines
March 16, 2026 5:40 PM - StreetInsider
Form 4 Esperion Therapeutics, For: Mar 13 Filed by: Looker Benjamin
March 16, 2026 4:22 PM - SEC Filing
Form 4 Esperion Therapeutics, For: Mar 13 Filed by: Koenig Sheldon L.
March 16, 2026 4:22 PM - SEC Filing
Form 4 Esperion Therapeutics, For: Mar 13 Filed by: Halladay Benjamin
March 16, 2026 4:20 PM - SEC Filing
Esperion's bempedoic acid gets class 1 recommendations in new guidelines
March 16, 2026 6:31 AM - StreetInsider
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
March 16, 2026 6:30 AM - StreetInsider
Esperion Therapeutics (ESPR) PT Raised to $5 at Citizens After Q4 Results
March 13, 2026 5:40 AM - StreetInsider
Full Article List
